Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Myeloid, Acute 20Lung Neoplasms 19Burkitt Lymphoma 18Recurrence 14Lymphoma 14Hodgkin Disease 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10Lymphoma, Mantle-Cell 10Lymphoma, B-Cell 10Leukemia 10Carcinoma, Non-Small-Cell Lung 10Medulloblastoma 8Neoplasms, Germ Cell and Embryonal 7Neoplasms 7Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma, T-Cell 6Brain Neoplasms 6Sarcoma, Ewing 5Retinoblastoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Immunoblastic Lymphadenopathy 5Ependymoma 5Rhabdomyosarcoma 4Rhabdoid Tumor 4

Interventions

asciminib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × Etoposide × 1 year × Clear all
NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡